University of Maryland awarded $200M for flu vaccine research - Technical.ly Baltimore

Sciences

Sep. 20, 2019 5:14 pm

University of Maryland awarded $200M for flu vaccine research

With one of the largest-ever contracts for the university's Baltimore-based School of Medicine, researchers are looking to strengthen protections against a disease that impacts millions.
University of Maryland School of Medicine.

University of Maryland School of Medicine.

Photo by Wikimedia Commons user Alx bio, used under Creative Commons license.

Researchers in Baltimore will be putting years of vaccine expertise toward strengthening flu shots.

The University of Maryland School of Medicine was awarded a contract worth up to $200 million from the National Institute of Allergies and Infectious Diseases to improve influenza vaccines.

It’s routine to get a flu shot, but the virus is complex and remains far-reaching. About 43 million Americans were impacted in 2018-2019.The goal of the research is to develop a universal influenza vaccine that protects against new strains of the disease and is longer-lasting.

Research is being conducted under a program called Collaborative Influenza Vaccine Innovation Center (CIVICs). Drawing on a team that brings expertise in pre-clinical studies, clinical trials and human challenge studies. A new “clinical core” will be established at the school to evaluate improved flu vaccines, and work toward a universal vaccine.

“While current influenza vaccines have been critical in reducing disease, the virus is constantly changing,” said Dr. Kathleen Neuzil, who is leading the research and is director of the school’s Center for Vaccine Development and Global Health (CVD), in a statement. “The CIVICs program will address the need to develop and test influenza vaccines that protect against new and emerging strains, and ultimately prevent more disease.”

Advertisement

The funding marks one of the largest-ever research contracts awarded to the Baltimore-based University of Maryland School of Medicine, with funding coming over seven years.

For its part, CVD has 40 years of vaccine development expertise. In recent years, researchers there played a key role as trial of a vaccine for ebola were accelerated amid an outbreak in Africa.

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Pinkaloo raises $1.25M, led by Baltimore’s Squadra VC

Introducing ‘Off the Sidelines,’ a new podcast series about startup investing

emocha and University of Maryland School of Pharmacy join forces on medication reviews

SPONSORED

Baltimore

How independence fuels confidence and professional development at SmartLogic

Baltimore

SmartLogic

Operations Manager

Apply Now

Philadelphia, PA

Vistar Media

Software Engineer

Apply Now

Baltimore, MD

SmartLogic

Chief of Staff

Apply Now

Investment gives Vista Equity Partners majority stake in Maryland’s Sonatype

Cybersecurity startup Code Dx wins $2M seed investment at DataTribe Challenge

Cybrary’s $15M Series B will be used to expand its cybersecurity training platform

SPONSORED

Baltimore

How this lawyer is helping entrepreneurs bark up the right tree

Philadelphia, PA - Center City

Odessa

Sr. Business Analyst, ERP Implementations

Apply Now

Baltimore, MD

SmartLogic

Developer

Apply Now

Philadelphia, PA

URBN

IT Recruiter

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!